| Literature DB >> 36243806 |
Guan-Hua Su1,2, Yi Xiao1,2, Lin Jiang1,2, Ren-Cheng Zheng3, He Wang3, Yan Chen4, Ya-Jia Gu5,6, Chao You7,8, Zhi-Ming Shao1,2.
Abstract
BACKGROUND: Tumor-infiltrating lymphocytes (TILs) have become a promising biomarker for assessing tumor immune microenvironment and predicting immunotherapy response. However, the assessment of TILs relies on invasive pathological slides.Entities:
Keywords: Magnetic resonance imaging (MRI); Radiomics; Triple-negative breast cancer (TNBC); Tumor microenvironment (TME); Tumor-infiltrating lymphocytes (TILs)
Mesh:
Substances:
Year: 2022 PMID: 36243806 PMCID: PMC9571493 DOI: 10.1186/s12967-022-03688-x
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 8.440
Fig. 1Schematic of the study. Tumor-infiltrating lymphocytes (TILs) densities were evaluated on H&E slides and were split into high and low TILs based on cut-off of 20%. Study cohort was randomly divided into training and validation cohort at a 7:3 ratio and similar high TILs proportion was kept in training and validation cohort. Regions of interest (ROIs) were segmented from the original breast MRI. Radiomics features were extracted from ROIs and were used to develop a TILs prediction model. Transcriptomics analysis was performed to further illustrate the radiomics model
Comparison of the basic information of the training and validation sets
| Clinical characters | Level | Training set (n = 98) | Validation set (n = 41) | p value |
|---|---|---|---|---|
| Age (years, mean [SD]) | – | 54.28 (10.57) | 54.61 (12.25) | 0.872 |
| Menopause (%) | False | 31 (32.3) | 13 (32.5) | 1 |
| True | 65 (67.7) | 27 (67.5) | ||
| T stage (%) | 1 | 48 (49.0) | 14 (34.1) | 0.206 |
| 2 | 46 (46.9) | 26 (63.4) | ||
| 3 | 4 (4.1) | 1 (2.4) | ||
| N stage (%) | 0 | 56 (58.3) | 27 (65.9) | 0.226 |
| 1 | 23 (24.0) | 12 (29.3) | ||
| 2 | 12 (12.5) | 2 (4.9) | ||
| 3 | 5 (5.2) | 0 (0.0) | ||
| Stromal TILs (%) | High | 56 (57.1) | 23 (56.1) | 1 |
| Low | 42 (42.9) | 18 (43.9) | ||
| Ki-67 [mean (SD)] | – | 56.99 (21.90) | 64.27 (26.14) | 0.094 |
| Molecular subtype (%) | BLIS | 29 (29.6) | 13 (31.7) | 0.709 |
| IM | 21 (21.4) | 9 (22.0) | ||
| LAR | 17 (17.3) | 8 (19.5) | ||
| MES | 16 (16.3) | 3 (7.3) | ||
| Unknown | 15 (15.3) | 8 (19.5) |
SD standard deviation, BLIS basal-like immune-suppressed, IM immunomodulatory, LAR luminal androgen receptor, MES mesenchymal-like
Fig. 2Training and validation of the TILs-predicting radiomics (Rad-TILs) model. A, B Representative TNBC pathological samples with high (A) and low (B) stromal tumor-infiltrating lymphocytes (sTILs). C Heatmap showing the distribution of selected radiomics feature value in high and low sTILs samples from the training and validation cohorts. D, E The correlation between sTILs status evaluated by pathologists (high and low sTILs) and TILs scores predicted by the radiomics model (Radiomics TILs score) in the training cohort (D) and validation cohort (E). F, G Receiver operating characteristic (ROC) curve of Rad-TILs model in the training cohort (F) and validation cohort (G)
Fig. 3Immune related pathways enriched in the high TILs samples predicted by the radiomics model. A Differentially expressed genes between high and low TILs samples predicted by the radiomics model (high and low Rad-TILs). B Representative upregulated pathways in high Rad-TILs by KEGG enrichment analysis. C Top 10 upregulated and downregulated pathways in high Rad-TILs by GSEA based on KEGG database. D Top 10 upregulated and downregulated pathways in high Rad-TILs by GSEA based on Reactome databases. E Representative immune-related pathways enriched in high Rad-TILs by GSEA based on KEGG database
Fig. 4Clinicopathological and tumor microenvironmental (TME) characteristics of high and low Rad-TILs. A, C Lymph node status (A), sTILs quantification (B) and CD8 score (C) of high and low Rad-TILs. D–F Equivalent intrinsic subtypes (D), equivalent mRNA subtypes (E), and distinct TME subtypes (F) between high and low Rad-TILs. The p values were calculated using Wilcoxon test (for lymph node status, sTILs quantification and CD8 score) and Fisher’s exact test (for intrinsic subtypes, mRNA subtypes and TME subtypes)
Fig. 5Inflamed TME in high Rad-TILs revealed by transcriptomics analysis. A Comparison of immune cell subpopulation between high and low Rad-TILs. The p values were calculated using Wilcoxon test. Specific p values were denoted on each cell type. B, C Expression of immune-related signatures in high and low Rad-TILs. Cytolytic activity (B) and T cell inflamed gene expression profiles (GEPs) (C) of two groups. The p values were calculated using Wilcoxon test. D, J Distinct expression of immune-related molecules on cell surface, including costimulators (D), coinhibitors (E) and major histocompatibility complex (J) between two groups. Distinct immune-related secretary molecules, including interleukins (F), chemokines (G), interferons (H) and colony-stimulating factors (I) between two groups. The p values calculated by Wilcoxon test were adjusted to false discovery rate (FDR) using the Benjamini–Hochberg procedure in multiple comparisons. Specific FDR values were denoted on each molecule